MD, MSc, MBA
Associate Professor, Medicine-Oncology
Section Chief, Breast Oncology
UNC-Chapel Hill
Breast Cancer
UNC Breast Center
Meet Katherine Reeder-Hayes
Area of Interest
Reeder-Hayes is a health services researcher with a focus on breast cancer treatment and survival disparities and real-world effectiveness of cancer treatments. Her areas of expertise include analyses of large linked data resources including insurance claims, electronic health record data, cancer registry and vital statistics data. She has also worked extensively with qualitative and survey studies of cancer patients and with behavioral interventions in cancer patient populations.
She is a contributor to the Carolina Breast Cancer Study, a large prospective cohort study of racially diverse women with newly diagnosed breast cancer across the state of North Carolina, and co-leads the GETSET trial, a national study to improve the support of breast cancer survivors taking oral hormonal therapies.
Awards and Honors
- Robert L. Ney Award, UNC Department of Internal Medicine, 2007
- James & Orleans Strange Fellowship, Auburn University School of Business, 1999-2000
- Dean’s Select Scholarship, Vanderbilt University, 1994-1998
News and Stories
Cancer center researchers to present latest findings at international breast cancer meeting
The San Antonio Breast Cancer Symposium features presentations outlining basic, translational, clinical and community-based study findings focused on advancing the prevention, diagnosis and treatment of breast cancer.
Researchers receive five-year, $1.2 million ACS grant to develop, test new methods to track cancer screening
A group of UNC Lineberger researchers led by Katie Reeder-Hayes, MD, MSc, MBA, will develop new methods to measure and map cancer screening across North Carolina.
Race and geography linked to different risks of breast cancer treatment delays
A study led by Katherine Reeder-Hayes, MD, MBA, MS, found that Black patients and patients living in certain regions experience greater delays.
Specific sequence of drugs reduces cost of treating metastatic breast cancer while preserving quality of life
Researchers developed three different computer models to predict how a hypothetical set of patients with specific types of metastatic breast cancer would respond to different sequences and types of chemotherapy.
